BioCentury | Dec 6, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2018

New Therapeutic Targets and Biomarkers: November 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Nov 17, 2018
Preclinical News

Spotlight co-founder uses CRISPR screen to ID T cell regulator genes for cancer

Spotlight Therapeutics Inc. (Hayward, Calif.) co-founder Alexander Marson and colleagues at University of California San Francisco developed a CRISPR-based screen to identify genes that control T cell replication and immunosuppression, and used the results to...
BioCentury | May 28, 2015
Distillery Techniques

Techniques: RAS p21 protein activator GTPase activating protein 1 (RASA1; RASGAP; p120GAP); N-acetylated α-linked acidic dipeptidase-like 2 (NAALADL2)

Biomarkers RASA1 NAALADL2 RAS p21 protein activator GTPase activating protein 1 RASGAP p120GAP National Cancer Institute BC Staff...
BioCentury | Jun 29, 2009
Company News

Med Discovery, University of Lausanne deal

...exclusive, worldwide rights to the university's peptides derived from RAS p21 protein activator GTPase activating protein 1 ( RASA1 , RASGAP , p120GAP...
BioCentury | Jun 4, 2009
Distillery Therapeutics

Indication: Cancer

...Publication and contact information Cancer Cancer RAS p21 protein activator (GTPase activating protein) 1 (RASA1; RASGAP...
...non-natural d-version of a cell-permeable fusion peptide consisting of the Tat protein and portions of RASGAP...
Items per page:
1 - 5 of 5